Skip to main content

Site notifications

We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.

Sub menu

News and events
Contact us
About us

Search

Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

You are here

Home
Resources and guidance
Sponsors

Merck Sharp & Dohme (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (139)
ARTG (79)
Prescription medicine registration (64)
Australian public assessment report (AusPar) (33)
Designation or determination (31)
Prescription medicine evaluation (7)
Prescription medicine decision summary (3)

Date

2026 (11)
2025 (33)
2024 (23)
2023 (32)
2022 (29)
2021 (31)
2020 (37)
2019 (52)
2018 (23)
2017 (3)
2016 (10)
2015 (6)
2014 (9)
2013 (13)
2012 (6)
2011 (3)
2009 (10)
2008 (1)
2007 (2)
2006 (8)
2005 (1)
2003 (1)
2002 (3)
2000 (1)
1998 (1)
1997 (5)
1993 (1)
1991 (1)

Search

Sponsor content

356 result(s) found, displaying 61 to 70

ZERBAXA (Merck Sharp & Dohme (Australia) Pty Ltd)

14 June 2024

Prescription medicine registration

Active ingredients: ceftolozane sulfate, tazobactam sodium.
STEGLUJAN 5/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 5 mg/100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STEGLUJAN 15/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 15 mg/100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)

4 June 2024

Prescription medicine registration

Active ingredients: pembrolizumab.
SEGLUROMET 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
SEGLUROMET 2.5/1000 ertugliflozin/metformin hydrochloride 2.5 mg/1000 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
SEGLUROMET 7.5/500 ertugliflozin/metformin hydrochloride 7.5 mg/500 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
SEGLUROMET 7.5/1000 ertugliflozin/metformin hydrochloride 7.5 mg/1000 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STEGLATRO 15 ertugliflozin 15 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STEGLATRO 5 ertugliflozin 5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd

Pages

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Page 10
Page 11
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

© Commonwealth of Australia